Healthcare utilization and costs associated with acute lymphoblastic leukemia in children with and without Down syndrome

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Pediatric Blood & Cancer

• Publication date

  2022-06-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.29829PMID 35674471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

  2022cited by this paper
• Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

  2021cited by this paper
• Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b‐precursor acute lymphoblastic leukaemia: Case reports and literature review

  2021cited by this paper
• Leukemia Risk in a Cohort of 3.9 Million Children With and Without Down Syndrome.

  2021cited by this paper
• Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

  2021cited by this paper
• Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study

  2021cited by this paper
• Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report.

  2020cited by this paper
• Outcome of children and adolescents with Down syndrome treated on Dana‐Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00–001 and 05‐001

  2018cited by this paper
• Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

  2018cited by this paper
• Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

  2018cited by this paper
• Out‐of‐pocket medical costs and third‐party healthcare costs for children with Down syndrome

  2017cited by this paper
• Faculty Opinions recommendation of Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

  2016cited by this paper
• Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

  2016cited by this paper
• The validity of pediatric cancer diagnoses in a population-based general cancer registry in Ontario, Canada

  2016cited by this paper
• Phase-specific healthcare costs of cervical cancer: estimates from a population-based study.

  2016cited by this paper
• Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

  2015cited by this paper
• Health system costs for stage-specific breast cancer: a population-based approach.

  2014cited by this paper
• Hospitalizations and associated costs in a population-based study of children with Down syndrome born in Florida.

  2014cited by this paper
• Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

  2014cited by this paper
• Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

  2014cited by this paper
• How I treat ALL in Down's syndrome: pathobiology and management.

  2014cited by this paper
• Guidelines on Person-Level Costing Using Administrative Databases in Ontario

  2013cited by this paper
• Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

  2013cited by this paper
• Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

  2012cited by this paper
• Direct health care costs of children and adolescents with Down syndrome.

  2011cited by this paper
• Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

  2011cited by this paper
• Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.

  2010cited by this paper
• Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.

  2008cited by this paper
• Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.

  2006cited by this paper
• Congenital abnormalities and childhood cancer

  2005cited by this paper
• Congenital abnormalities and childhood cancer

  2005cited by this paper
• Epidemiology of leukemia in children with Down syndrome

  2005cited by this paper
• Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG‐1952

  2005cited by this paper
• Childhood cancer registries in Ontario, Canada: Lessons learned from a comparison of two registries

  2003cited by this paper

• No citing papers are available for this paper.